🔗 Share this article

As the United States undertakes sweeping revisions to its vaccination recommendations, an unexpected name appears unexpectedly: Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccinations throughout the pandemic and has concentrated on potential deaths following Covid immunization in her recent tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Schedule

Agency leaders had intended to announce major changes to the pediatric vaccine schedule recently, aligning the US with the Danish national calendar, sources say – a significant shift that would put the US out of step with many the international standard with insufficient data for improved outcomes. The announcement has been delayed until the next year.

In place of Vinay Prasad, Dr. Høeg is scheduled to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to head the center this year.

Consolidating Power at the FDA

This interim role may indicate a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing some pediatric immunization guidelines in the US so as to align more like the Danish model, a nation with nationalized medicine and a citizenry about the population of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Qualifications

Høeg has no apparent background in medication creation, oversight or leadership, which has been typical for former heads of the CBER. She has served at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, stated Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a major agency. She lacks background in industry regulation.”

Past directors of CBER would “grasp regulatory frameworks and the science of pharmaceutical innovation”, said Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who led CBER have had.”

This division has an vast range of responsibilities at the FDA, the former commissioner stated.

“The public just pays attention on the new drug program, but the off-patent medication office clears a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and every single one must be managed,” Dr. Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management element to the position, which supervises in excess of 5,000 personnel. “It’s a huge management job, if you execute it properly,” the former official added.

Official Statement and Disputed Initiatives

Regarding questions about Høeg’s credentials and whether this appointment represents increased cooperation among regulatory chiefs on vaccines, a representative said that the “concerns are based on inaccurate premises”.

“Her experience matches the functions of her job,” the representative said, citing the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's recently launched priority voucher program, a contentious expedited drug-approval program that allegedly concerned her predecessors. “How are these therapies being picked for this fast-track system? Who makes the calls?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of most medications, except for shots.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a more documented, if problematic, track record, critics have noted. She published a research paper using unconfirmed volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new federal leadership included changing guidelines for novel immunizations and halting “unnecessary” immunizations, she stated after the election on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding adolescent males from receiving COVID-19 vaccines.

“She is an thorough true believer who commences with her conclusions and works backwards to retrofit the data in a highly misleading, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|